SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSpark is drawing attention after a steep selloff to fresh lows, with traders noting that miners have lagged Bitcoin and attributing pressure to a broader sector downturn and concerns about financing costs and execution. The community is split between buying what some see as an oversold dip and expecting further declines, with short-selling and frustration over management also prominent.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereums uneven price action and repeated tests of support are driving discussion, with traders debating whether the pullback will deepen or give way to a rebound. Bearish posts cite weak momentum and failed resistance, while bulls point to dip buying, accumulation, and institutional use of Ethereums network.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomms planned global, performance-focused layoffs are a major focus, with the number of cuts undisclosed; traders disagree over whether the restructuring signals cost discipline or reflects deeper execution concerns. The discussion also looks ahead to earnings as a test of the companys promises, while some traders point to QCOM holding up relatively well against semiconductor peers.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Globals long-term LNG supply agreements, including the 20-year ConocoPhillips deal and a reported China Gas contract, are drawing attention as traders weigh the added customer validation and contracted-volume visibility. Some see the agreements as positive, while others argue that long-dated contracts may limit upside from spot-price spikes and point to debt, arbitration and execution risks.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRPs ongoing selloff and weak price action dominate the discussion, with traders watching support levels and blaming broader crypto weakness, whale selling, or Ripples token supply. Bears argue that escrow releases and stablecoin use limit XRP demand, while bulls point to adoption news and upcoming Ripple eventsbut many question why positive developments have not lifted the token.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas upcoming full-year earnings report is the main focus, with traders positioning around the results as the stock trades near record highs. The community is split between bullish momentum and confidence in the business, and concerns that the shares are overbought or vulnerable to a pullback.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Aetnas weaker Medicare Advantage star ratings are drawing attention, with traders concerned about lost quality bonuses and pressure on CVSs insurance margins. Some argue the setback may already be priced in or expect a recovery, while others emphasize the ratings as a meaningful headwind.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is drawing attention after reaching a fresh high, with traders linking energy-sector strength to elevated crude prices and supply concerns tied to conflict and shipping risks around the Strait of Hormuz. Some see the breakout as confirmation of the uptrend, while others warn that oil-price volatility and potential profit-taking could undermine the move.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforces agreement to acquire customer-engagement software company Braze is driving discussion, with traders weighing the deals strategic fit for its AI-powered marketing tools against concerns about the purchase price and integration risks. The reaction is mixed, with some viewing the acquisition as an expansion of Salesforces AI capabilities and others calling it an expensive or questionable use of capital.

dogwifhat (WIF) is a Solana-based memecoin featuring a Shiba Inu dog wearing a pink knitted hat that has become a central figure in the 2024-2026 market. Originally launched anonymously in late 2023, the project operates on a decentralized, community-driven model with no formal venture capital backing or complex tokenomics. It represents a cultural phenomenon on the Solana blockchain that celebrates whimsy and simplicity over technical complexity, focusing on its identity as a playful mascot for the digital finance era. The project’s main value proposition is its "Pure Meme Identity," as it maintains a strict focus on its meme origins without forced utility or a pivot toward DeFi and gaming.  The project embodies the community-driven nature of the Solana ecosystem, prioritizing "vibes" and meme-sharing as its primary growth drivers. It follows a "hat stays on" philosophy, maintaining a singular focus on its core meme rather than building a complex ecosystem. While the project does not have a formal governance structure or DAO, decisions are largely driven by social consensus among the community and key influencers. Notable community initiatives include the "Sphere Wif Hat" campaign, which raised nearly $700,000 in USDC in March 2024 to put the mascot on the Las Vegas Sphere. However, after a year of negotiations and delays, organizers officially abandoned the advertisement on March 31, 2025, and initiated a full refund process for donors.  The initial team behind dogwifhat remains anonymous, which is a standard practice within the memecoin sector. The coin's narrative is heavily influenced by prominent crypto personalities, most notably Ansem, who was a key figure in the project's early viral growth and subsequent marketing initiatives. Regarding integrations, WIF has deep liquidity across major Solana decentralized exchanges like Jupiter and Raydium, is available on the Unichain network via official contract bridging, and is listed on major centralized exchanges including Binance, Coinbase, Kraken, and Bybit.  WIF is a purely speculative asset whose value is primarily driven by community sentiment and meme culture rather than traditional utility. It was launched without a presale or significant venture capital allocation, meaning the token's supply is fully circulating. The project has achieved a "blue chip" status in the memecoin space, often serving as a beta-play for the broader health of the Solana ecosystem. No native decentralized applications or trading bots have been officially launched by the core team, as the project maintains its focus on its identity as "literally a dog wif a hat".

dogwifhat

WIF is drawing attention for persistent selling and prolonged, largely flat-to-red trading, with many holders expressing frustration and alleging price manipulation. A smaller bullish contingent views the weakness as an accumulation opportunity and hopes for a rebound alongside a broader crypto or meme-coin rally.

statis crypto Watchlist

Bitcoin

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ultragenyxs recent FDA approvals of FAYUVI and GENGLYCOS, alongside priority review voucher sales that add non-dilutive cash, are driving discussion about new revenue streams and the companys path toward profitability. Many traders view the developments as undervalued catalysts, while others are frustrated by the stocks choppy price action and question whether launch growth and cost reductions will translate into a sustained recovery.

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week

Ultragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.

Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?

Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.

Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity

Equity

The FDA awarded the voucher after approving Genglycos, a glycogen storage disease type Ia treatment, in August.


Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREPR NewswireNEW YORK, Sept. 24, 2026 NEW YORK, Sept. 24, 2026...

RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results

Ultragenyx shares are trading around $16 after gaining about 9% this week, rebounding from the $12.73 low hit earlier this month. 


RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy

Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndrome Type A, backed by durable clinical data.

Ultragenyx Gets A ‘Much-Needed Win,’ Says Cantor – Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy

Wall Street raised Ultragenyx’s price target after the U.S. Food and Drug Administration approved Fayuvi to treat children with Sanfilippo syndrome Type A.


Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?

Ultragenyx (RARE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>A Priority Review Voucher lets its recipient request a faster review of a future drug application or sell the voucher to another company.</li><li>The company said proceeds will support rare-disease programs and its path toward profitability.</li><li>The latest deal marks Ultragenyx’s third PRV sale, with the previous two in 2018.</li></ul>Shares of Ultragenyx Pharmaceutical (RARE) were in focus after the biotech company agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210 million, giving it sizeable non-dilutive capital to support its pipeline.<a href="https://stocktwits.com/symbol/RARE">RARE shares</a> were up 4% at the time of writing, bucking the broader market drawdown and on track for their biggest single-day gain&nbsp;so far this month.<h2 class="st-heading-2">Genglycos Is Ultragenyx’s Third PRV Sale</h2>A Priority Review Voucher (PRV) lets its recipient request a faster review of a future drug application with the U.S. Food and Drug Administration (FDA) or sell the voucher to another company.The FDA awarded the voucher after approving Genglycos, a glycogen storage disease type Ia treatment, in August. Ultragenyx said proceeds from the sale will help fund development of additional rare and ultra-rare disease treatments.“Monetizing this PRV provides significant non-dilutive capital to advance our efforts to bring forward first-ever therapies for rare and ultra-rare diseases, and supports our path to profitability,” said Howard Horn, Ultragenyx’s CFO.The latest deal marks Ultragenyx’s third PRV sale, after the company sold its first two vouchers in 2018 for a combined $210.6 million.<h2 class="st-heading-2">RARE Still Has Four Therapies In Pipeline</h2>Ultragenyx’s pipeline includes four experimental therapies for brain, liver and muscle-related diseases. It also markets four drugs — Crysvita, Dojolvi, Evkeeza and Mepsevii — for a range of rare bone, metabolic, cholesterol and genetic disorders.The latest cash infusion adds to Ultragenyx’s $436 million in cash, cash equivalents and marketable securities as of June 30.<h2 class="st-heading-2">Retail Sees ‘Huge’ Buying Opportunity</h2>Retail sentiment surrounding RARE on Stocktwits remained in the ‘bearish’ zone over the past 24 hours.<img src="https://news.stocktwits-cdn.com/RARE_e434df825a.png" alt="RARE.png">One user saw a “huge buying opportunity” with RARE close to a breakout.<stembedurl>https://stocktwits.com/Idontknownothing55/message/665956550</stembedurl>The stock has been under significant selling pressure this year, falling more than 36%.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/fcel-stock-slumps-amid-cfo-transition-but-retail-calls-ex-xylem-hire-an-encouraging-sign/cZDvghkRBmt">&nbsp;FCEL Stock Slumps Amid CFO Transition — But Retail Calls Ex-Xylem Hire An ‘Encouraging Sign’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ultragenyx Pharmaceutical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The FDA awarded the voucher after approving Genglycos, a glycogen storage disease type Ia treatment, in August.

Ultragenyx Pharmaceutical Inc

SPDR S&P Biotech ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$15.65
Prev Close	$15.95
Open	$15.92
Dividend Yield	0.00%
50-Day Moving Average	$17.95
Beta	1.04
Avg. Volume	7.13M
PE Ratio	-2.68

52-Week High	$39.89
52-Week Low	$12.73
Market Capitalization	$1.54B
EPS (Annual)	-$5.83
Price to Book	-5.29
Revenue Per Employee	$490,882.57

Feed

News

Sentiment

Earnings

Fundamentals

Info

RARE Fundamentals